Law Firm Detail

On December 04, Axonics Modulation Technologies, Inc.—a California-based privately-held medical device company developing an innovative neuromodulation platform based on miniaturized rechargeable technology and developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of bladder and bowel dysfunction—announced that the United States Patent and Trademark Office (USPTO) has granted Axonics seven new U.S. patents along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

The most recently issued patents (US patent nos. 9,802,038; 9,802,051; 9,700,731; 9,770,596; 9,728,981; 9,789,325; and 9,780,596) range in subject matter and include coverage of the Company’s external pulse generator, implantable lead design, and internal system electronics.

In this regard, Axonics’ CEO Raymond W. Cohen said, “The continued growth of the Axonics patent portfolio further demonstrates the level of innovation and commitment to technical excellence behind the clinical and business milestones that the Company has reported in 2017. With these seven new U.S. patents, we presently have more than 100 granted and 80 pending patent applications in our portfolio in various jurisdictions around the world.”

The Axonics patent portfolio represents technology internally developed by Axonics and technology developed under license from the Alfred Mann Foundation.